ArticleJournal for immunotherapy of cancer2021

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.

April A N Rose et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.